欧洲介入性 X 射线市场中的造影剂和成像剂 – 行业趋势和 2030 年预测

欧洲介入X射线造影剂和成像剂市场分析及规模

中风和心血管疾病患病率的快速增长是推动欧洲介入性 X 射线造影剂和成像剂市场增长的主要因素。此外，对微创手术的需求不断增长、辐射量减少和成像质量提高的启示、对微创诊断和外科手术的需求不断增长以及慢性病患病率和发病率不断上升也促进了市场的整体增长。然而，翻新介入性 X 射线系统的日益普及预计将阻碍市场的增长。                               

Data Bridge Market Research 分析，欧洲介入 X 射线造影剂和成像剂市场在 2022 年的规模为 12 亿美元，预计到 2030 年将达到 34.6 亿美元，预计在 2023-2030 年预测期内的复合年增长率为 5.13%。这表明，由于整个地区癌症病例数量的增加，“肿瘤学”市场价值在欧洲介入 X 射线造影剂和成像剂市场的应用领域中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

欧洲介入X射线造影剂和成像剂市场范围和细分

Market Definition

Contrast and imaging agents in interventional X-Ray basically improves the health-related issues. Contrast material, is also referred as contrast agents/media, it improves image quality produced by computed tomography (CT), x-rays and others, which help to distinguish abnormal conditions within the body.            

Europe Contrast and Imaging Agents in Interventional X-Ray Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurological disorders in Europe has led to an increased demand for interventional X-Ray procedures. Contrast and imaging agents are crucial in diagnosing and treating these conditions, driving the market's growth.

• Advancements in Imaging Technologies

Continuous advancements in interventional X-Ray technologies, including fluoroscopy, angiography, and computed tomography (CT), have increased the need for high-quality contrast and imaging agents. These agents enhance the visibility and accuracy of imaging, which is essential for effective diagnosis and treatment planning.

• Growing Investment in Research and Development 

Both pharmaceutical companies and research institutions are investing significantly in the research and development of imaging technologies. Additionally, increased healthcare investments in research and development have driven innovation in contrast and imaging agents, making them more effective and safer for patients.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Rising Demand for Minimally Invasive Procedures

There is a growing trend toward minimally invasive interventional procedures in Europe due to their reduced patient recovery times and shorter hospital stays. This shift presents an opportunity for contrast and imaging agents, as they play a crucial role in enhancing visualization during minimally invasive interventions, such as angioplasty and stent placement.

• Expanding Applications in Oncology

Interventional radiology procedures, including image-guided tumor ablations and selective internal radiation therapy (SIRT), are increasingly used in cancer treatment. The development of specialized contrast and imaging agents tailored for oncology applications offers significant growth potential, as it enables precise tumor targeting and monitoring.

Restraints/ Challenges

• Rising Demand for Minimally Invasive Procedures

There is a growing trend toward minimally invasive interventional procedures in Europe due to their reduced patient recovery times and shorter hospital stays. This shift presents an opportunity for contrast and imaging agents, as they play a crucial role in enhancing visualization during minimally invasive interventions, such as angioplasty and stent placement.

• Expanding Applications in Oncology

Interventional radiology procedures, including image-guided tumor ablations and selective internal radiation therapy (SIRT), are increasingly used in cancer treatment. The development of specialized contrast and imaging agents tailored for oncology applications offers significant growth potential, as it enables precise tumor targeting and monitoring.

• Regulatory Challenges and Safety Concerns

Stringent regulatory requirements and safety concerns surrounding contrast and imaging agents can pose significant restraints. Regulatory changes or safety issues may lead to delays in product approvals or recalls, affecting market access and profitability for manufacturers.

• High Cost of Imaging Agents

Contrast and imaging agents can be expensive, especially when used in large quantities or for complex interventional procedures. The high cost of these agents can limit their adoption, particularly in healthcare systems with budget constraints.

This Europe contrast and imaging agents in interventional X-Ray market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe contrast and imaging agents in interventional X-Ray market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2021, Guerbet and Bracco Imaging announced a Europe collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent
• In December 2021, Qaelum NV announced a strategic partnership with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks

Europe Contrast and Imaging Agents in Interventional X-Ray Market Scope

欧洲介入性 X 射线造影剂和成像剂市场根据药剂类型、应用和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

代理类型

• 碘造影剂
• 钡基造影剂
• 微泡造影剂
• 金纳米粒子造影剂
• 其他的

应用

• 心脏病学
• 胃肠病学
• 神经病学
• 肿瘤学
• 泌尿科
• 普通外科

最终用户

• 影像中心
• 医院
• 诊所
• 诊断中心
• 门诊手术中心
• 私人诊所

欧洲介入性 X 射线造影剂和成像剂市场区域分析/见解

对欧洲介入性X射线市场的造影剂和成像剂进行了分析，并按国家、药剂类型、应用和最终用户提供了市场规模洞察和趋势。

欧洲介入X射线造影剂和成像剂市场报告涵盖的国家包括德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其和欧洲其他地区。

由于欧洲地区慢性病患病率上升，德国在欧洲介入性X射线造影剂和成像剂市场占据主导地位。   

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

欧洲介入性 X 射线造影剂和成像剂市场还为您提供了每个国家/地区资本设备医疗保健支出增长情况的详细市场分析、欧洲介入性 X 射线造影剂和成像剂市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对欧洲介入性 X 射线造影剂和成像剂市场的影响。数据适用于 2015-2020 年的历史时期。 

介入X射线造影剂和成像剂的竞争格局和欧洲市场份额分析

欧洲介入性 X 射线造影剂和成像剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对欧洲介入性 X 射线造影剂和成像剂市场的关注有关。

欧洲介入X射线造影剂和成像剂市场的一些主要参与者包括：

• 通用电气（美国）
• 布拉科（意大利）
• Ziehm Imaging GmbH（德国）
• Lantheus Medical Imaging, Inc.（美国）
• 日立有限公司 (日本)
• 格尔伯特（法国）
• 西门子（德国）
• FUJIFILM VisualSonics Inc（加拿大）
• Jodas Expoim（印度）
• Technix Spa（意大利）
• Hologic Inc（美国）
• 美敦力（爱尔兰）
• TAEJOON PHARM（韩国）
• Unijules Life Sciences Ltd.（印度）
• JBChemicals & Pharmaceuticals Ltd (印度)
• Novalek Pharmaceuticals Pvt. Ltd.（印度）
• Nano Therapeutics Pvt Ltd（印度）

SKU-29357